Liabeuf S, et al. - This double-blind, placebo-controlled, randomized study was performed on normophosphatemic patients with CKD stage 3b/4, to assess the impact of sevelamer carbonate on serum C-terminal fibroblast growth factor 23 levels in these subjects. Findings demonstrated that normophosphatemic CKD patients receiving sevelamer carbonate for a 12-week period exhibited reduced phosphaturia with unaltered levels of serum phosphorus, however, this treatment intervention did not significantly modified serum C-terminal fibroblast growth factor 23 and intact fibroblast growth factor 23 or α-klotho levels.